Graves Disease Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Novartis, AdvanceCor, Apitope, Worg Pharmaceuticals, AV7 Limited

The Graves Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Graves Disease pipeline products will significantly revolutionize the Graves Disease market dynamics.
DelveInsight's "Graves Disease Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Graves Disease, historical and forecasted epidemiology as well as the Graves Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Graves Disease market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Graves Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Graves Disease Market Insights [https://www.delveinsight.com/report-store/graves-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Graves Disease Market Report:

* The Graves Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
* In August 2023, The investigational new drug (IND) application for TOUR006, developed by Tourmaline Bio, received clearance from the US Food and Drug Administration (FDA). This enables the commencement of a Phase IIb trial to evaluate TOUR006's efficacy in treating thyroid eye disease (TED), also known as Graves' ophthalmopathy. The study aims to compare the effects of TOUR006 at 20mg and 50mg doses with a placebo in patients with moderate to severe TED who are in the active phase of the disease.
* In January 2023, Immunovant Sciences GmbH has launched a study titled "A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants With Active Thyroid Eye Disease (TED).
* According to the Graves' disease and thyroid foundation, Graves' disease, also known as toxic diffuse goiter, is the most common cause of hyperthyroidism - a disorder that occurs when the thyroid gland makes more thyroid hormone than the body needs
* According to National Institute of Diabetes and Digestive and Kidney Diseases (n.d.), the disease affects about 1 in 200 people in the United States and is the most common cause of hyperthyroidism
* The National Institute of Diabetes and Digestive and Kidney Diseases (n.d.), estimates that 30 percent of people who develop Graves' disease will get a mild case of Graves' ophthalmopathy. Up to 5 percent will get severe Graves' ophthalmopathy
* Key Graves Disease Companies: Novartis, AdvanceCor, Apitope, Worg Pharmaceuticals, AV7 Limited, and others
* Key Graves Disease Therapies: Secukinumab, Cyclopeptides, ATX-GD-59, K1-70, and others
* The Graves Disease epidemiology based on gender analyzed that the Graves' Disease is 7-8 times more common in women than men

Graves Disease Overview

Graves' disease is an autoimmune disorder that affects the thyroid gland, a small butterfly-shaped gland located in the front of the neck. In Graves' disease, the immune system mistakenly attacks the thyroid gland, causing it to produce excessive amounts of thyroid hormones (hyperthyroidism).

Get a Free sample for the Graves Disease Market Report -

https://www.delveinsight.com/sample-request/graves-disease-market [https://www.delveinsight.com/sample-request/graves-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Graves Disease Market

The dynamics of the Graves Disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.

"The DAVIAD project successfully resulted in the manufacture GMP grade ATX-GD-59 and completion of pharmacodynamic and toxicology studies in order to progress the therapeutic vaccine into a Phase I/IIa clinical trial. In the clinical trial, the vaccine was proven to be safe and well tolerated."

Graves Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Download the report to understand which factors are driving Graves Disease epidemiology trends @ Graves Disease Epidemiological Insights [https://www.delveinsight.com/sample-request/graves-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Graves Disease Epidemiology Segmentation:

The Graves Disease market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

* Total Prevalence of Graves Disease
* Prevalent Cases of Graves Disease by severity
* Gender-specific Prevalence of Graves Disease
* Diagnosed Cases of Episodic and Chronic Graves Disease

Graves Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Graves Disease market or expected to get launched during the study period. The analysis covers Graves Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Graves Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

To know more about Graves Disease treatment, visit @ Graves Disease Medications [https://www.delveinsight.com/sample-request/graves-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Graves Disease Therapies and Key Companies

* Secukinumab: Novartis
* Cyclopeptides: AdvanceCor
* ATX-GD-59: Apitope/ Worg Pharmaceuticals
* K1-70: AV7 Limited

Graves Disease Market Drivers

* Increasing in the prevalence of Graves Disease
* Increased public awareness about the treatment of Graves' disease

Graves Disease Market Barrriers

* High cost of the treatment
* Complications associated with the treatment

Scope of the Graves Disease Market Report

* Study Period: 2019-2032
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Graves Disease Companies: Novartis, AdvanceCor, Apitope, Worg Pharmaceuticals, AV7 Limited, and others
* Key Graves Disease Therapies: Secukinumab, Cyclopeptides, ATX-GD-59, K1-70, and others
* Graves Disease Therapeutic Assessment: Graves Disease current marketed and Graves Disease emerging therapies
* Graves Disease Market Dynamics: Graves Disease market drivers and Graves Disease market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Graves Disease Unmet Needs, KOL's views, Analyst's views, Graves Disease Market Access and Reimbursement

Discover more about therapies set to grab major Graves Disease market share @ Graves Disease market forecast [https://www.delveinsight.com/sample-request/graves-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Graves Disease Market Report Introduction

2. Executive Summary for Graves Disease

3. SWOT analysis of Graves Disease

4. Graves Disease Patient Share (%) Overview at a Glance

5. Graves Disease Market Overview at a Glance

6. Graves Disease Disease Background and Overview

7. Graves Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Graves Disease

9. Graves Disease Current Treatment and Medical Practices

10. Graves Disease Unmet Needs

11. Graves Disease Emerging Therapies

12. Graves Disease Market Outlook

13. Country-Wise Graves Disease Market Analysis (2019-2032)

14. Graves Disease Market Access and Reimbursement of Therapies

15. Graves Disease Market Drivers

16. Graves Disease Market Barriers

17. Graves Disease Appendix

18. Graves Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=graves-disease-market-to-observe-impressive-growth-during-the-forecast-period-20232032-evaluates-delveinsight-novartis-advancecor-apitope-worg-pharmaceuticals-av7-limited]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.